Dr. Richard Goldberg on Pembrolizumab for Lynch Syndrome Patients
Richard Goldberg, MD, Physician-in-Chief, Professor of Medicine, the Klotz Family Chair in Cancer Research, Associate Director of Outreach, Ohio State University Comprehensive Cancer, James Cancer Hospital and Solove Research Institute, discusses immunotherapy treatment for colorectal cancer patients with Lynch syndrome.
Richard Goldberg, MD, Physician-in-Chief, Professor of Medicine, the Klotz Family Chair in Cancer Research, Associate Director of Outreach, Ohio State University Comprehensive Cancer, James Cancer Hospital and Solove Research Institute, discusses immunotherapy treatment for colorectal cancer patients with Lynch syndrome.
A study looking at pembrolizumab in patients with colon cancer, found that the PD-1 inhibitor demonstrated a 60% response rate amongst heavily pretreated patients with Lynch syndrome.
Lynch syndrome affects about 4% of those with advanced colorectal cancer. These patients have mismatched repair and hyper-mutated tumors which can be difficult to treat, said Goldberg.
